This study investigates a treatment for adults living with Obstructive Sleep Apnea, a condition where breathing repeatedly stops and starts during sleep, specifically in those who also live with overweight or obesity. The participants in this study are already using Positive Airway Pressure therapy, which is a device that uses air pressure to keep the airways open during sleep. The goal of the study is to evaluate the effectiveness and safety of the drug AMG 133, also known as maridebart cafraglutide, compared to a placebo.

During the study, participants will receive either maridebart cafraglutide or a placebo through a subcutaneous injection, which means the medicine is administered just under the skin. The study will monitor changes in the Apnea-Hypopnea Index, an assessment used to measure the severity of breathing interruptions during sleep. Other factors being observed include body weight and levels of C-reactive protein, which is a substance in the blood that can indicate inflammation in the body.